key: cord-0730062-058a1d1t
authors: Patanè, Salvatore
title: Letter to the Editor Regarding “Pulmonary Embolism Prophylaxis in Patients With COVID-19: an Emerging Issue”, Heart Lung Circ. 2021;30(10):1435–41.
date: 2021-11-04
journal: Heart Lung Circ
DOI: 10.1016/j.hlc.2021.10.008
sha: 03e051e926a3b94cc9aa67c9a708806a3c62566b
doc_id: 730062
cord_uid: 058a1d1t

nan

Heart, Lung and Circulation (2021 To the Editor, I read the article by Sanidas and colleagues [1] with great interest and congratulate the authors on their excellent work. However, I would like to draw attention to several points. Recent findings suggest that SARS-CoV-2 controls the expression of host regulatory molecules such as miRNAs and transcription factors (TFs), often regulating gene expression at transcriptional and post-transcriptional levels and forming highly complex network interactions [2] . Research has identified four miRNAs (hsa-mir-9-5p, hsa-mir-324-3p, hsa-mir-1827, and hsa-mir-1277-5p) and TFs (EP300, MYC, E2F1, and SP1) that co-regulate important target genes responsible for SARS-CoV-2 host invasion [2] . Studies have found evidence supporting common molecular trajectories of SARS-CoV-2 with clotting, pulmonary embolism, pulmonary oedema, and systematic inflammation, showing both fibrinolysis as a major pathway leading to D-dimer increase and cytokines TGF-b and TNF-a as major regulators of fibrinolysis controlling proteins PAI-1 and plasminogen activators also highlighting the role of hsa-mir-9-5p, hsa-mir-324-3p, EP300, and SP1 on pulmonary embolism [2] . It has also been reported that in the circulating exosomes of high D-dimer COVID-19 patients (cut-off 3 mg/mL) there is significant miR-424 upregulation and miR-103a, miR-145, and miR-885 downregulation. Exosomal miR-424 is an independent thromboembolic event predictor in COVID-19 patients [3, 4] , whereas miR-103a independently regulates D-dimer levels [4] . Furthermore, miR-885 targets von Willebrand factor and miR-145 targets tissue factor [3, 4] , showing negative correlations with their respective targets [3] . The findings of Sanidas and colleagues [1] add significant information to previously published data; however, also evaluating these aspects would be useful for better understanding of the interplay between pulmonary embolism in patients with COVID-19 and its complex regulatory network. 

Pulmonary embolism prophylaxis in patients with COVID-19: an emerging issue

nSARS-Cov-2, pulmonary edema and thrombosis: possible molecular insights using miRNA-gene circuits in regulatory networks

Non-coding RNAs in COVID-19: emerging insights and current questions. Non-coding RNA

Exosomal microRNAs drive thromboembolism in COVID-19

Ó 2021 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ)

Pulmonary Embolism Prophylaxis in Patients With COVID-19: an Emerging Issue